Register for free to
view the full innovation profile.
Discovered a series of small molecule analogues (SMAs) of ES62 that are able to suppress inflammatory responses both in vitro and in vivo.
About
Scientists at Strathclyde have produced a series of small molecule analogues (SMAs) of ES62 that are able to suppress inflammatory responses both in vitro and in vivo but only when aberrant hyper-inflammatory responses have been invoked. These compounds have the potential to provide a range of highly selective and safe drugs that do not immune-compromise the patient. Like ES62 itself, the SMA’s are protective in models of arthritis, asthma, fibrosis, obesity, systemic lupus erythematosus (SLE)(including associated cardiovascular disease) and skin inflammation. The SMAs modify signalling through toll-like receptors by binding to the adaptor protein MyD88 preventing the stimulation of release of pro-inflammatory cytokines, bringing immunological signalling back to normal levels. This project seeks to optimise the structures of new compounds to produce clinical candidates for the treatment of inflammatory diseases.
Key Benefits
• New class of anti-inflammatory agents with good druggability and easy synthetic access • Broad portfolio of potential target diseases • Selective immunomodulation as the patient remains 'immune-competent' and able to fight off infections • Compounds are both therapeutic and prophylactic
Applications
This technology has the potential to treat many inflammatory-based conditions such as rheumatoid arthritis, SLE and asthma. According to a Global Burden of Diseases (GBD) 2017 study there were over 19 million individuals suffering with rheumatoid arthritis. 5.4 million people in the UK are currently being treated for asthma, and it is estimated that around 5 million people worldwide live with some degree of lupus condition. 39% of adults worldwide are overweight with 13% of adults classed as obese. These compounds have multi-indication potential allowing for multiple revenue streams.